A phase III trial investigating the safety and efficacy of M7824 compared to pembrolizumab as first-line treatment of advanced NSCLC patients with high PD-L1-tumor expression is currently ongoing (NCT03631706). Here, CD274 is linked to non-small cell lung carcinoma.